Epirus Biopharmaceuticals (EPRS) Getting Favorable Press Coverage, Study Shows

Media headlines about Epirus Biopharmaceuticals (NASDAQ:EPRS) have been trending positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Epirus Biopharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.181767736213 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

ILLEGAL ACTIVITY NOTICE: “Epirus Biopharmaceuticals (EPRS) Getting Favorable Press Coverage, Study Shows” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/10/09/epirus-biopharmaceuticals-eprs-getting-favorable-press-coverage-study-shows.html.

Epirus Biopharmaceuticals Company Profile

Insider Buying and Selling by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)

Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply